WO1998010770A1 - Oral compositions containing fluocinonide - Google Patents

Oral compositions containing fluocinonide Download PDF

Info

Publication number
WO1998010770A1
WO1998010770A1 PCT/EP1997/004820 EP9704820W WO9810770A1 WO 1998010770 A1 WO1998010770 A1 WO 1998010770A1 EP 9704820 W EP9704820 W EP 9704820W WO 9810770 A1 WO9810770 A1 WO 9810770A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
fluocinonide
glyceryl monooleate
composition
gingivitis
Prior art date
Application number
PCT/EP1997/004820
Other languages
French (fr)
Inventor
Thomas Buser
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Priority to AU43015/97A priority Critical patent/AU4301597A/en
Priority to CA002266028A priority patent/CA2266028A1/en
Priority to JP51322198A priority patent/JP2001505544A/en
Priority to EP97919036A priority patent/EP0973525A1/en
Publication of WO1998010770A1 publication Critical patent/WO1998010770A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Definitions

  • This invention relates to the use the glyceryl monooleate in the preparation of a spreadable, topical composition for the treatment or prophylaxis of oral ulcerations, inflammation and lesions of the oral cavity.
  • the invention relates to a topical composition comprising fluocinonide and glyceryl monooleate .
  • Oral ulceration other lesions and inflammation in the oral cavity can be very painful.
  • preparations for the treatment of oral ulcerations For example carbenoxolone sodium can be helpful in promoting healing of mild oral lesions, lozenges and oral pastes containing corticosteroids are used for treating apthous non-specific ulcers, salicylates can be used in mild inflammatory and painful oral lesions, and benzydamine hydrochloride has a topical anti-inflammatory and analgesic effect and is used as a mouthwash or spray for oral ulcerations.
  • a difficulty of treating oral ulcerations with preparations such as sprays, lozenges and mouthwash is that the active agent of the preparation is only transiently in contact with the ulcer. Even with gelatin based pastes, which have a protective effect for non-infected ulcers, it is difficult to keep them on the lesion for a prolonged period.
  • a mucoprotectant is orabase which contains carboxymethyl cellulose sodium, pectin and gelatin. This composition, however, has an uncomfortable gritty mouth feel.
  • Fluocinonide is a corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, ointment, or scalp application containing 0.05%.
  • fluocinonide is used in an adhesive base to effectively treat oral vesiculoerosive diseases.
  • the adhesive base was orabase.
  • fluocinonide is again used in adhesive base, this time to treat oral lichen planus.
  • the adhesive base was 40% hypromellose (hydroxypropyl methyl cellulose) in white soft paraffin.
  • the present inventor has now surprisingly found an effective medicament for treating oral ulcerations, inflammation, and lesions of the oral cavity which comprises fluocinonide or a physiologically acceptable derivative thereof and glyceryl monooleate, such as monoolein, as a spreadable mucoadhesive base.
  • glyceryl monooleate such as monoolein
  • the glyceryl monooleate is conveniently spread in a thin film over, for example, the ulcer and forms an adhesive bond with the mucous of the ulcer, which in turn maintains the active agent in contact with the ulcer for a prolonged period.
  • Monoolein is a mixture of the glycerides of oleic acid and other fatty acids, consisting mainly of the glyceryl monooleate.
  • a commercial form of monoolein is sold by Eastman Chemicals (e.g. at Hemel Hempstead, UK or Denver,
  • Myverol a water soluble drug into an oil matrix
  • Monoolein is normally formulated in its fully hydrated cubic phase (which contains up to about 40% water) to produce its advantageous sustained release properties (J. Phy. Chem.1989 , 93, 7304-7314 and EP-A-0 314 689).
  • a composition comprising monoolein and an active such as metronidazole (an anti-bacterial) is described in EP-A-0 671 175 and equivalent US-A-5 261 164 as a sustained release product for treating periodontal disease.
  • the composition is injected into the periodontal pocket, preferably by a syringe.
  • elyzolTM Such a product is sold under the trade name elyzolTM which is issued with a disposable applicator for the treatment of chronic periodontal disease.
  • elyzolTM is issued with a disposable applicator for the treatment of chronic periodontal disease.
  • a similar periodontal type application of monoolein is disclosed in J.Clin. Periodontal 1992; 19:687- 692.
  • a first aspect of the present invention there is provided use of fluocinonide or a physiologically acceptable derivative thereof together with glyceryl monooleate having a water content of less than about 20% w/w in the preparation of a spreadable topical medicament for the treatment or prophylaxis of oral ulcerations, inflammation and lesions of the buccal mucosa, tongue, palate, gingivae, and lips.
  • physiologically acceptable derivative we mean a derivative which is metabolised in vivo, such as by the enzymes in the oral cavity, to the same active metabolite as fluocinonide, and in particular includes physiologically acceptable salts.
  • monoolein (CAS Registry No. 25496-72-4) is used in the composition of the invention.
  • monoolein we mean a product which consists predominantly of glyceryl monooleate, although various other glycerides of oleic acid and other fatty acids could be present.
  • references to glyceryl monooleate should be construed also as a reference to monoolein and visa versa.
  • a particularly preferred form of monoolein is sold by Eastman Chemical under the trade name of MyverolTM.
  • the glyceryl monooleate (or monoolein) has a water content of less than about 5% w/w, more preferably less than about 2% w/w and optimally has a water content of substantially zero (i.e. pure glyceryl monoleate/monoolein) .
  • lesion we mean to include papule, nodule, weal, vesicle, bulla, pustule, plaque, scale, excoriation, scar, and lichenification.
  • Most oral ulcerations or lesions should respond to treatment with a composition of the present invention particularly including the following: oral aphthous ulcers, oral mucositis (including mucositis neuroticans agranulocytica) , oral Crohn's disease, orofacial granulomatosis, and cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquamative gingivitis and gingivitis associated with lichen planus, and oral vesiculerosive diseases.
  • oral aphthous ulcers oral mucositis (including mucositis neuroticans agranulocytica) , oral Crohn's disease, orofacial granulomatosis, and cicatricial pemphigoid
  • oral erosive lichen planus including the following: oral aphthous ulcers, oral mucositis (including mucositis neuroticans agranulocytica)
  • composition of the invention is of particular benefit in the treatment or prophylaxis of cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquanative gingivitis and gingivitis associated with lichen planus.
  • Oral mucositis is an inflammation of the oral mucous surface and, for example, can result from chemotherapy.
  • Symptoms of oral Crohn's disease can include thickening of the mucous membranes of the mouth and lip.
  • Symptoms of orofacial granulomatosis can include furrowing of the tongue, thickening of the lower lip and buccal mucosa, and recurrent aphthous ulcers.
  • Cicatricial pemphigoid is a chronic vesiculobullous disease that primarily involves the mucous membranes. It is an autoimmune condition and is characterised by the formation of subepithelial bullae.
  • Oral erosive lichen planus is a common condition of the oral mucosa, usually of no identifiable aetrology. However a variety of drugs may provoke such a condition and certain of these drugs notably NSAIDs favour the induction of erosions.
  • composition of the invention is ideally suited for treating oral ulceration, inflammation and lesions of the tongue, palate, lips, gingivae and the buccal mucosa.
  • Optional components which can also be used in the composition include flavourings, surfactants, penetration enhancers, antioxidants, polymers, opacifiers, viscosity modifying agents including hydrocarbon waxes or oils such as glycerol .
  • white soft paraffin wax is used to improve the rheological behaviour of glyceryl monooleate (i.e. improve its spreadability) .
  • titanium dioxide as an opacifier
  • lidocaine hydrochloride as an anaesthetic
  • benzyl alcohol as a penetration enhancer
  • ascorbyl palmitate as an antioxidant
  • the amount of each component in a formulation can vary.
  • fluocinonide could be used at 0.01 to 0.05% w/w, preferably 0.015 to 0.035% w/w and most preferably about 0.025% w/w.
  • Glyceryl monooleate can be present at 30% to 90% w/w, preferably 50% to 70% w/w and most preferably about 60% w/w.
  • the formulation would be made up with other optional components.
  • a hydrocarbon wax such as white soft paraffin, is desirably used at 20% to 60% w/w, preferably 30% to 50% w/w, most preferably about 40% w/w.
  • an anaesthetic agent such as lidocaine, it is desirably used at 1% to 5% w/w, preferably about 3% w/w.
  • a particularly preferred embodiment of the invention includes fluocinonide or a physiologically acceptable salt thereof, at 0.015% to 0.035% w/w, glyceryl monooleate at 40% to 60% w/w, hydrocarbon wax, preferably white soft paraffin, at 39.965% to 39.985% w/w.
  • composition of the invention is typically supplied from a tube or pump dispenser and spread topically using the finger tip in a smearing action over, for example, the oral ulcer.
  • a thin and very mucoadhesive film is formed which is comfortable and convenient for the patient.
  • the glyceryl monooleate film protects the ulcer from further infection and, because it > is substantially insoluble in saliva, it prevents the active agent from being washed off the ulcer. As such, with intermittent applications a therapeutically effective amount of active agent can be maintained in continuous contact with the ulcer thereby accelerating healing.
  • glyceryl monooleate having a water content of less than about 20% w/w as a mucoadhesive in the preparation of a spreadable fluocinonide medicament for the topical treatment of oral ulcerations, inflammation, or lesions of the oral cavity, particularly the buccal mucosa, tongue, palate, gingivae, and lips.
  • fluocinonide or a physiologically acceptable derivative thereof and glyceryl monooleate having a water content of less than about 20% w/w in the preparation of a spreadable medicament for the topical treatment of oral ulcerations, inflammation, or lesions of the oral cavity.
  • a method of treating oral ulcerations, inflammation, or lesions of the oral cavity comprising spreading topically over the ulcer lesion, or inflammed mucosa, a pharmaceutical formulation comprising an effective amount of fluocinonide or a physiologically acceptable derivative thereof, and glyceryl monooleate- having a water content of less than about 20% w/w.
  • fluocinonide can particularly treat oral cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquemative gingivitis, and gingivitis associated with oral lichen planus
  • a yet further aspect of the invention relates to the use of fluocinonide in the preparation of a medicament (in any composition) for the treatment of these oral disorders.
  • Example 2 Childhood Cicatricial Pemphigoid Presenting as Desquamative Gingivitis
  • a diagnosis of benign mucous membrane cicatracial pemphigoid (localised to the gingivae) was made.
  • This treatment was subsequently replaced by the mucoadhesive fluocinonide composition according to Example 1 and the patient instructed to apply this composition to the gingivae 4 times daily for 6 weeks.
  • the fluocinonide gel of Example 1 was prescribed to patients with oral erosive lichen planus refractory to conventional topical steroid preparation. Patients were asked to apply the gel 3 times daily to the erosions for a period of 2 weeks .
  • the fluocinonide gel of Example 1 was prescribed to several patients with desquamative gingivitis associated with lichen planus, and was found to be extremely beneficial .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A topical composition containing fluocinonide in a base of glyceryl monooleate with a water content of less than about 20 % W/W is provided for the treatment of oral ulcerations, inflammation and lesions of the oral cavity. The composition is smeared thinly over the ulcer and forms a very mucoadhesive film which holds the fluocinonide in contact with the ulcer for a prolonged period. The composition is particularly useful for the treatment of oral aphthous ulcers, oral mucositis (including mucositis neuroticans agranulocytica), oral Crohn's disease, orofacial granulomatosis, and cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquamative gingivitis and gingivitis associated with lichen planus, and oral vesiculerosive diseases.

Description

ORAL COMPOSITIONS CONTAINING FLUOCINONIDE
This invention relates to the use the glyceryl monooleate in the preparation of a spreadable, topical composition for the treatment or prophylaxis of oral ulcerations, inflammation and lesions of the oral cavity. In particular the invention relates to a topical composition comprising fluocinonide and glyceryl monooleate .
Oral ulceration (or mouth ulcers) other lesions and inflammation in the oral cavity can be very painful. There are various preparations for the treatment of oral ulcerations. For example carbenoxolone sodium can be helpful in promoting healing of mild oral lesions, lozenges and oral pastes containing corticosteroids are used for treating apthous non-specific ulcers, salicylates can be used in mild inflammatory and painful oral lesions, and benzydamine hydrochloride has a topical anti-inflammatory and analgesic effect and is used as a mouthwash or spray for oral ulcerations. A difficulty of treating oral ulcerations with preparations such as sprays, lozenges and mouthwash is that the active agent of the preparation is only transiently in contact with the ulcer. Even with gelatin based pastes, which have a protective effect for non-infected ulcers, it is difficult to keep them on the lesion for a prolonged period.
TM
An example of a mucoprotectant is orabase which contains carboxymethyl cellulose sodium, pectin and gelatin. This composition, however, has an uncomfortable gritty mouth feel.
Fluocinonide is a corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, ointment, or scalp application containing 0.05%.
In Arch. Dermatol . Vol 116, Aug 1980, pp. 98 to 901 fluocinonide is used in an adhesive base to effectively treat oral vesiculoerosive diseases. The adhesive base was orabase. In Oral Surg. Med. Oral Pathol . 1993; 75: 181 -5, fluocinonide is again used in adhesive base, this time to treat oral lichen planus. The adhesive base was 40% hypromellose (hydroxypropyl methyl cellulose) in white soft paraffin.
The present inventor has now surprisingly found an effective medicament for treating oral ulcerations, inflammation, and lesions of the oral cavity which comprises fluocinonide or a physiologically acceptable derivative thereof and glyceryl monooleate, such as monoolein, as a spreadable mucoadhesive base. The glyceryl monooleate is conveniently spread in a thin film over, for example, the ulcer and forms an adhesive bond with the mucous of the ulcer, which in turn maintains the active agent in contact with the ulcer for a prolonged period..
Monoolein is a mixture of the glycerides of oleic acid and other fatty acids, consisting mainly of the glyceryl monooleate. A commercial form of monoolein is sold by Eastman Chemicals (e.g. at Hemel Hempstead, UK or Denver,
TM
USA) under the trade name Myverol . The manufacturers recommended uses of Myverol™ are: for sustained release formulations, for topical permeation enhancement, for solubilisation of a water soluble drug into an oil matrix, and for sustained release microspheres . Monoolein is normally formulated in its fully hydrated cubic phase (which contains up to about 40% water) to produce its advantageous sustained release properties (J. Phy. Chem.1989 , 93, 7304-7314 and EP-A-0 314 689).
A composition comprising monoolein and an active such as metronidazole (an anti-bacterial) is described in EP-A-0 671 175 and equivalent US-A-5 261 164 as a sustained release product for treating periodontal disease. The composition is injected into the periodontal pocket, preferably by a syringe. Such a product is sold under the trade name elyzol™ which is issued with a disposable applicator for the treatment of chronic periodontal disease. A similar periodontal type application of monoolein is disclosed in J.Clin. Periodontal 1992; 19:687- 692.
In Pharmaceutical Technology Europe Feb 1995, pl4-16, various phases of monoolein are described. Primarily there is the fully hydrated cubic phase which consists of about 2/3 lipid and 1/3 water by water, and is used in the sustained release of drugs. The lamellar phase has a water content of about 5 to 20% w/w and in a water-rich environment will spontaneously swell to the cubic phase. The mucosal adhesion force (to a pig's tongue) is twice as great for the lamellar phase as for the cubic phase. Other precursor phases to the fully swelled cubic phase are pure monoolein (substantially zero water content) and the reversed micellar phase (0% to 5% w/w water) . If such a precursor phase is applied to a wet surface for example the gums or any mucosa, the system will absorb water from the surroundings .
It is an object of the present invention to provide an effective treatment for oral ulceration, inflammation and lesions of the oral cavity, in particular of the tongue, gingivae, lips, palate and buccal mucosa.
Accordingly in a first aspect of the present invention there is provided use of fluocinonide or a physiologically acceptable derivative thereof together with glyceryl monooleate having a water content of less than about 20% w/w in the preparation of a spreadable topical medicament for the treatment or prophylaxis of oral ulcerations, inflammation and lesions of the buccal mucosa, tongue, palate, gingivae, and lips.
By physiologically acceptable derivative, we mean a derivative which is metabolised in vivo, such as by the enzymes in the oral cavity, to the same active metabolite as fluocinonide, and in particular includes physiologically acceptable salts.
Preferably, monoolein (CAS Registry No. 25496-72-4) is used in the composition of the invention. By monoolein, we mean a product which consists predominantly of glyceryl monooleate, although various other glycerides of oleic acid and other fatty acids could be present. Hereinafter references to glyceryl monooleate should be construed also as a reference to monoolein and visa versa. A particularly preferred form of monoolein is sold by Eastman Chemical under the trade name of Myverol™. Preferably the glyceryl monooleate (or monoolein) has a water content of less than about 5% w/w, more preferably less than about 2% w/w and optimally has a water content of substantially zero (i.e. pure glyceryl monoleate/monoolein) .
By lesion we mean to include papule, nodule, weal, vesicle, bulla, pustule, plaque, scale, excoriation, scar, and lichenification.
Most oral ulcerations or lesions should respond to treatment with a composition of the present invention particularly including the following: oral aphthous ulcers, oral mucositis (including mucositis neuroticans agranulocytica) , oral Crohn's disease, orofacial granulomatosis, and cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquamative gingivitis and gingivitis associated with lichen planus, and oral vesiculerosive diseases.
The composition of the invention is of particular benefit in the treatment or prophylaxis of cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquanative gingivitis and gingivitis associated with lichen planus. Oral mucositis is an inflammation of the oral mucous surface and, for example, can result from chemotherapy.
Symptoms of oral Crohn's disease can include thickening of the mucous membranes of the mouth and lip.
Symptoms of orofacial granulomatosis can include furrowing of the tongue, thickening of the lower lip and buccal mucosa, and recurrent aphthous ulcers.
Cicatricial pemphigoid is a chronic vesiculobullous disease that primarily involves the mucous membranes. It is an autoimmune condition and is characterised by the formation of subepithelial bullae.
Oral erosive lichen planus is a common condition of the oral mucosa, usually of no identifiable aetrology. However a variety of drugs may provoke such a condition and certain of these drugs notably NSAIDs favour the induction of erosions.
The composition of the invention is ideally suited for treating oral ulceration, inflammation and lesions of the tongue, palate, lips, gingivae and the buccal mucosa.
Optional components which can also be used in the composition include flavourings, surfactants, penetration enhancers, antioxidants, polymers, opacifiers, viscosity modifying agents including hydrocarbon waxes or oils such as glycerol . In a preferred embodiment white soft paraffin wax is used to improve the rheological behaviour of glyceryl monooleate (i.e. improve its spreadability) .
Other preferred optional components are titanium dioxide as an opacifier, lidocaine hydrochloride as an anaesthetic, benzyl alcohol as a penetration enhancer and ascorbyl palmitate as an antioxidant.
The amount of each component in a formulation can vary. Thus for example fluocinonide could be used at 0.01 to 0.05% w/w, preferably 0.015 to 0.035% w/w and most preferably about 0.025% w/w. Glyceryl monooleate can be present at 30% to 90% w/w, preferably 50% to 70% w/w and most preferably about 60% w/w. Where the total weight is less than 100% w/w, the formulation would be made up with other optional components. For example, a hydrocarbon wax, such as white soft paraffin, is desirably used at 20% to 60% w/w, preferably 30% to 50% w/w, most preferably about 40% w/w. If an anaesthetic agent, such as lidocaine, is present, it is desirably used at 1% to 5% w/w, preferably about 3% w/w.
A particularly preferred embodiment of the invention includes fluocinonide or a physiologically acceptable salt thereof, at 0.015% to 0.035% w/w, glyceryl monooleate at 40% to 60% w/w, hydrocarbon wax, preferably white soft paraffin, at 39.965% to 39.985% w/w.
The composition of the invention is typically supplied from a tube or pump dispenser and spread topically using the finger tip in a smearing action over, for example, the oral ulcer. In this way a thin and very mucoadhesive film is formed which is comfortable and convenient for the patient. In addition, the glyceryl monooleate film protects the ulcer from further infection and, because it > is substantially insoluble in saliva, it prevents the active agent from being washed off the ulcer. As such, with intermittent applications a therapeutically effective amount of active agent can be maintained in continuous contact with the ulcer thereby accelerating healing.
Further aspects of the invention are as follows:
1. The use of glyceryl monooleate having a water content of less than about 20% w/w as a mucoadhesive in the preparation of a spreadable fluocinonide medicament for the topical treatment of oral ulcerations, inflammation, or lesions of the oral cavity, particularly the buccal mucosa, tongue, palate, gingivae, and lips.
2. The use of fluocinonide or a physiologically acceptable derivative thereof and glyceryl monooleate having a water content of less than about 20% w/w in the preparation of a spreadable medicament for the topical treatment of oral ulcerations, inflammation, or lesions of the oral cavity.
3. A method of treating oral ulcerations, inflammation, or lesions of the oral cavity comprising spreading topically over the ulcer lesion, or inflammed mucosa, a pharmaceutical formulation comprising an effective amount of fluocinonide or a physiologically acceptable derivative thereof, and glyceryl monooleate- having a water content of less than about 20% w/w.
4. Since we have also discovered that fluocinonide can particularly treat oral cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquemative gingivitis, and gingivitis associated with oral lichen planus, a yet further aspect of the invention relates to the use of fluocinonide in the preparation of a medicament (in any composition) for the treatment of these oral disorders.
The invention will now be described by way of example with reference to the following compositions.
Example 1
Active Constituent % w/w
Fluocinonide 0.025 Other Constituents
Myverol™ 18-99 60.0
(Monoglyceride)
White Soft Paraffin
(vasoline) 39.975 Total: 100.00
Example 2 : Childhood Cicatricial Pemphigoid Presenting as Desquamative Gingivitis
A fourteen year old girl presented with painful erythematous gingivae and a history of blister formation. A diagnosis of benign mucous membrane cicatracial pemphigoid (localised to the gingivae) was made. The patient was initially treated with a mouth rinse containing triamcinolone and chlortetracycline . This treatment was subsequently replaced by the mucoadhesive fluocinonide composition according to Example 1 and the patient instructed to apply this composition to the gingivae 4 times daily for 6 weeks. The desquamative gingivitis responded well to the mucoadhesive fluocinonide gel.
Example 3 : Oral Erosive Lichen Planus
The fluocinonide gel of Example 1 was prescribed to patients with oral erosive lichen planus refractory to conventional topical steroid preparation. Patients were asked to apply the gel 3 times daily to the erosions for a period of 2 weeks .
This limited study presents favourable results for that the use of the fluocinonide gel in the management of oral erosive lichen planus.
Example 4 ; Desquamative Gingivitis associated with Lichen Planus
The fluocinonide gel of Example 1 was prescribed to several patients with desquamative gingivitis associated with lichen planus, and was found to be extremely beneficial .

Claims

1. A spreadable mucoadhesive topical pharmaceutical composition for application to the oral mucosa, comprising fluocinonide or a physiologically acceptable derivative thereof and glyceryl monooleate having a water content of less than about 20% w/w.
2. A composition as claimed in Claim 1 wherein the glyceryl monooleate is present as monoolein.
3. A composition as claimed in Claims 1 or 2 wherein the glyceryl monooleate has a water content of less than about 5% w/w.
4. A composition as claimed in Claim 3 wherein the glyceryl monooleate is substantially water free.
5. A composition as claimed in any of the preceding claims comprising 0.015 to 0.035% w/w fluocinonide, 50 to 70% w/w glyceryl monooleate and white soft paraffin to 100% w/w.
6. Use of fluocinonide or a physiologically acceptable derivative thereof together with glyceryl monooleate having a water content of less than about 20% w/w in the preparation of a spreadable topical medicament for the treatment or prophylaxis of oral ulcerations, inflammation and lesions of the buccal mucosa, tongue, palate, gingivae, and lips.
7. Use as claimed in Claim 6 for the treatment or prophylaxis of oral aphthous ulcers, oral mucositis (including mucositis neuroticans agranulocytica) , oral Crohn's disease, orofacial granulomatosis, and cicatricial pemphigoid, oral erosive lichen planus, gingivitis such as desquamative gingivitis and gingivitis associated with lichen planus, and oral vesiculerosive diseases.
8. A method of treating oral ulcerations, inflammation, or lesions of the oral cavity comprising spreading topically over the ulcer, lesion, or inflammed mucosa a pharmaceutical formulation comprising an effective amount of fluocinonide or a physiologically acceptable derivative thereof, and glyceryl monooleate having a water content of less than about 20% w/w.
PCT/EP1997/004820 1996-09-11 1997-09-05 Oral compositions containing fluocinonide WO1998010770A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU43015/97A AU4301597A (en) 1996-09-11 1997-09-05 Oral compositions containing fluocinonide
CA002266028A CA2266028A1 (en) 1996-09-11 1997-09-05 Oral compositions containing fluocinonide
JP51322198A JP2001505544A (en) 1996-09-11 1997-09-05 Oral composition containing fluocinonide
EP97919036A EP0973525A1 (en) 1996-09-11 1997-09-05 Oral compositions containing fluocinonide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9618964.2A GB9618964D0 (en) 1996-09-11 1996-09-11 Oral composition
GB9618964.2 1996-09-11

Publications (1)

Publication Number Publication Date
WO1998010770A1 true WO1998010770A1 (en) 1998-03-19

Family

ID=10799761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/004820 WO1998010770A1 (en) 1996-09-11 1997-09-05 Oral compositions containing fluocinonide

Country Status (6)

Country Link
EP (1) EP0973525A1 (en)
JP (1) JP2001505544A (en)
AU (1) AU4301597A (en)
CA (1) CA2266028A1 (en)
GB (1) GB9618964D0 (en)
WO (1) WO1998010770A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011688A1 (en) * 2000-08-07 2002-02-14 Unilever N.V. Oral cosmetic composition comprising petroleum jelly enrobing an active agent
JP2003506397A (en) * 1999-08-06 2003-02-18 マックス−デルブルック−セントルム フュア モレキュラー メディツィン Implantable active ingredient depot
WO2014197398A1 (en) * 2013-06-03 2014-12-11 Tolmar, Inc. Corticosteroid compositions
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080219935A1 (en) * 2005-07-08 2008-09-11 Sang-Hoon Kwak Phase Transitive Breath Care Products

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097374A2 (en) * 1982-06-23 1984-01-04 Shionogi & Co., Ltd. Corticosteroid topical preparation
EP0187433A1 (en) * 1983-08-01 1986-07-16 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
WO1991007169A1 (en) * 1989-11-16 1991-05-30 Gordon Jay Dow Glyceryl acetate ointment vehicles
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US5407663A (en) * 1991-04-11 1995-04-18 Eisen; Drore Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents
EP0671175A2 (en) * 1989-11-17 1995-09-13 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
EP0676198A1 (en) * 1994-04-05 1995-10-11 Agis Industries (1983) Ltd Fungicidal compositions containing a combination of bifonazole and fluocinonide
JPH0948739A (en) * 1995-08-04 1997-02-18 Pola Chem Ind Inc Anti-inflammatory medicine composition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097374A2 (en) * 1982-06-23 1984-01-04 Shionogi & Co., Ltd. Corticosteroid topical preparation
EP0187433A1 (en) * 1983-08-01 1986-07-16 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
WO1991007169A1 (en) * 1989-11-16 1991-05-30 Gordon Jay Dow Glyceryl acetate ointment vehicles
EP0671175A2 (en) * 1989-11-17 1995-09-13 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5407663A (en) * 1991-04-11 1995-04-18 Eisen; Drore Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
EP0676198A1 (en) * 1994-04-05 1995-10-11 Agis Industries (1983) Ltd Fungicidal compositions containing a combination of bifonazole and fluocinonide
JPH0948739A (en) * 1995-08-04 1997-02-18 Pola Chem Ind Inc Anti-inflammatory medicine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 126, no. 18, 5 May 1997, Columbus, Ohio, US; abstract no. 242911, XP002050289 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506397A (en) * 1999-08-06 2003-02-18 マックス−デルブルック−セントルム フュア モレキュラー メディツィン Implantable active ingredient depot
WO2002011688A1 (en) * 2000-08-07 2002-02-14 Unilever N.V. Oral cosmetic composition comprising petroleum jelly enrobing an active agent
WO2014197398A1 (en) * 2013-06-03 2014-12-11 Tolmar, Inc. Corticosteroid compositions
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions

Also Published As

Publication number Publication date
GB9618964D0 (en) 1996-10-23
CA2266028A1 (en) 1998-03-19
JP2001505544A (en) 2001-04-24
AU4301597A (en) 1998-04-02
EP0973525A1 (en) 2000-01-26

Similar Documents

Publication Publication Date Title
EP0951287B1 (en) Oral composition comprising 5-aminosalicyclic acid
US6139861A (en) Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US5977087A (en) Topical preparation for treatment of aphthous ulcers and other lesions
JP2001508038A (en) Pharmaceutical gel preparations that can be applied to mucosal surfaces and body tissues
HU225235B1 (en) Pharmaceutical compositions comprising flurbiprofen
JPH059412B2 (en)
JP2001517621A (en) Non-steroidal anti-inflammatory composition for topical use
FR3035790A3 (en) DENTAL PREPARATION BASED ON HYALURONANE AND OCTENIDINE DICHLORHYDRATE
RU2420257C1 (en) Dental gel with chlorhexidine and dibunole for treatment of inflammatory diseases of parodentium and oral cavity mucosa
EP0973525A1 (en) Oral compositions containing fluocinonide
US20050214230A1 (en) Novel stomatological gel
JP2000063268A (en) Oral mucosa adhesion-type controlled release troche and periodontal disease therapeutic agent
JPH07267839A (en) Ointment composition adhesive to oral mucosa
CN114746082B (en) Anti-inflammatory liquid composition for intraoral mucosa coating, and pharmaceutical composition for preventing and/or treating stomatitis using the same
JP2000178185A (en) Oral mucous membrane-adhering type sustained release tablet
JP2001163745A (en) Patch agent for oral use
JPH0761933B2 (en) Oral composition
JPH0637379B2 (en) Topical for treatment of periodontal disease
JPH10338633A (en) Composition for treatment and prevention for periodontal disease
JPH09291018A (en) Composition for oral cavity
JPH0637383B2 (en) Oral anti-inflammatory agent
JPH06345630A (en) Anti-inflammatory composition for oral cavity
JPH11130644A (en) Composition for oral cavity
CN115501198B (en) Gum paste for relieving pain and diminishing inflammation and preparation method thereof
JP2001002590A (en) Oral mucous membrane-adhering type sustained release tablet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09147767

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2266028

Country of ref document: CA

Ref country code: CA

Ref document number: 2266028

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 513221

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997919036

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997919036

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997919036

Country of ref document: EP